Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FLXN

Flexion Therapeutics (FLXN) Stock Price, News & Analysis

Flexion Therapeutics logo

About Flexion Therapeutics Stock (NASDAQ:FLXN)

Key Stats

Today's Range
$9.12
$9.12
50-Day Range
$9.12
$9.44
52-Week Range
$4.30
$13.66
Volume
N/A
Average Volume
1.18 million shs
Market Capitalization
$458.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FLXN Stock News Headlines

“This Changes Everything” - Trump Hands Millions Massive IRS Gift
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
VIRI Virios Therapeutics, Inc.
Spyre Therapeutics Inc SYRE
PFIZER INC's Net Worth
See More Headlines

FLXN Stock Analysis - Frequently Asked Questions

Flexion Therapeutics, Inc. (NASDAQ:FLXN) issued its quarterly earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to the consensus estimate of $24.61 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), NVIDIA (NVDA), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Lipocine (LPCN), Micron Technology (MU) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
5/12/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLXN
Employees
257
Year Founded
2007

Profitability

Net Income
$-113,710,000.00
Net Margins
-100.32%
Pretax Margin
-100.32%

Debt

Sales & Book Value

Annual Sales
$85.55 million
Book Value
($0.34) per share

Miscellaneous

Free Float
45,727,000
Market Cap
$458.93 million
Optionable
Optionable
Beta
1.53

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:FLXN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners